Valeant Pharmaceuticals Intl (VRX) Earns “Sell” Rating from Wells Fargo & Co

Wells Fargo & Co restated their sell rating on shares of Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) in a report issued on Thursday.

A number of other analysts also recently issued reports on the stock. BMO Capital Markets increased their price target on shares of Valeant Pharmaceuticals Intl from $16.00 to $17.00 and gave the stock a market perform rating in a report on Monday, November 13th. Vetr raised shares of Valeant Pharmaceuticals Intl from a buy rating to a strong-buy rating and set a $19.72 price target on the stock in a report on Tuesday, December 5th. Royal Bank of Canada decreased their price objective on shares of Valeant Pharmaceuticals Intl from $21.00 to $18.00 and set a sector perform rating on the stock in a report on Friday, October 20th. Deutsche Bank set a $18.00 price objective on shares of Valeant Pharmaceuticals Intl and gave the company a hold rating in a report on Thursday, November 16th. Finally, Mizuho increased their price objective on shares of Valeant Pharmaceuticals Intl from $7.00 to $10.00 and gave the company an underperform rating in a report on Friday, December 15th. Six investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $18.20.

Shares of Valeant Pharmaceuticals Intl (NYSE VRX) traded up $0.80 during midday trading on Thursday, reaching $23.85. 22,316,334 shares of the company were exchanged, compared to its average volume of 21,791,100. Valeant Pharmaceuticals Intl has a 12-month low of $8.31 and a 12-month high of $24.43. The stock has a market capitalization of $8,313.92, a P/E ratio of 6.12, a PEG ratio of 0.72 and a beta of -0.22. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03.

In other Valeant Pharmaceuticals Intl news, Director John Paulson purchased 344,216 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were purchased at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the purchase, the director now owns 94,559 shares in the company, valued at approximately $1,361,649.60. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 5.87% of the company’s stock.

Large investors have recently bought and sold shares of the company. Riggs Asset Managment Co. Inc. lifted its stake in shares of Valeant Pharmaceuticals Intl by 118.2% in the third quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after buying an additional 4,512 shares in the last quarter. Cetera Investment Advisers purchased a new position in shares of Valeant Pharmaceuticals Intl in the second quarter worth about $192,000. Moors & Cabot Inc. lifted its stake in shares of Valeant Pharmaceuticals Intl by 32.3% in the second quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock worth $267,000 after buying an additional 3,725 shares in the last quarter. Harbour Capital Advisors LLC purchased a new position in shares of Valeant Pharmaceuticals Intl in the third quarter worth about $224,000. Finally, First Allied Advisory Services Inc. lifted its stake in shares of Valeant Pharmaceuticals Intl by 52.4% in the second quarter. First Allied Advisory Services Inc. now owns 16,465 shares of the specialty pharmaceutical company’s stock worth $287,000 after buying an additional 5,658 shares in the last quarter. 49.45% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Equities Focus and is the property of of Equities Focus. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.equitiesfocus.com/2018/01/07/valeant-pharmaceuticals-intl-vrx-earns-sell-rating-from-wells-fargo-co.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply